Patents by Inventor Karolina A. Hosiawa

Karolina A. Hosiawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230337646
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Application
    Filed: February 15, 2023
    Publication date: October 26, 2023
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 11617357
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: April 4, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 11612151
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: March 28, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Publication number: 20200221675
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Application
    Filed: December 30, 2019
    Publication date: July 16, 2020
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Publication number: 20200221676
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Application
    Filed: December 30, 2019
    Publication date: July 16, 2020
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 10561124
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: February 18, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 10246509
    Abstract: Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments. Methods for making antibody sequences that bind an antigen (e.g., a viral antigen) are provided, comprising immunizing a mouse with an antigen of interest, wherein the mouse comprises a single human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments, at the endogenous immunoglobulin heavy chain locus.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: April 2, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, John McWhirter, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20170332609
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Application
    Filed: May 2, 2017
    Publication date: November 23, 2017
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 9706759
    Abstract: Non-human animals, tissues, cells, and genetic material are provided that comprise a modification of an endogenous non-human heavy chain immunoglobulin sequence and that comprise an ADAM6 activity functional in a mouse, wherein the non-human animals express a human immunoglobulin heavy chain variable domain and a cognate human immunoglobulin ? light chain variable domain.
    Type: Grant
    Filed: December 17, 2012
    Date of Patent: July 18, 2017
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn Macdonald, Cagan Gurer, Karolina A. Hosiawa, Sean Stevens, Andrew J. Murphy
  • Patent number: 9516868
    Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
    Type: Grant
    Filed: August 2, 2011
    Date of Patent: December 13, 2016
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20150313193
    Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.
    Type: Application
    Filed: April 6, 2015
    Publication date: November 5, 2015
    Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
  • Patent number: 9035128
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: May 19, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Hosiawa
  • Patent number: 9012717
    Abstract: Genetically modified mice are provided that express human ? variable (hV?) sequences, including mice that express hV? sequences from an endogenous mouse ? light chain locus, mice that express hV? sequences from an endogenous mouse ? light chain locus, and mice that express hV? sequences from a transgene or an episome wherein the hV? sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human ? variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human ? variable sequences, including human antibodies, are provided.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: April 21, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Andrew J. Murphy, Karolina A. Hosiawa
  • Publication number: 20140130194
    Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 8, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20140130193
    Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 8, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20130323791
    Abstract: Mice having a restricted immunoglobulin heavy chain locus are provided, wherein the locus is characterized by a single polymorphic human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments. Methods for making antibody sequences that bind an antigen (e.g., a viral antigen) are provided, comprising immunizing a mouse with an antigen of interest, wherein the mouse comprises a single human VH gene segment, a plurality of human DH gene segments and a plurality of JH gene segments, at the endogenous immunoglobulin heavy chain locus.
    Type: Application
    Filed: July 17, 2013
    Publication date: December 5, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, John McWhirter, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20130198879
    Abstract: Mice, tissues, cells, and genetic material are provided that comprise a humanized heavy chain immunoglobulin locus, a humanized light chain locus that expresses a universal light chain, and a gene encoding an ADAM6 or ortholog or homolog or functional fragment thereof. Mice are provided that express humanized heavy chains comprising human variable domains, and that express humanized light chains comprising human variable domains wherein the light chains are derived from no more than one, or no more than two, light chain V and J or rearranged V/J sequences. Fertile male mice that express antibodies with universal light chains and humanized heavy chains are provided. Methods and compositions for making bispecific binding proteins are provided.
    Type: Application
    Filed: August 3, 2012
    Publication date: August 1, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20130045492
    Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.
    Type: Application
    Filed: June 5, 2012
    Publication date: February 21, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20120192300
    Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making light chain variable regions in mice, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, are provided.
    Type: Application
    Filed: March 6, 2012
    Publication date: July 26, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Robert Babb, John McWhirter, Lynn MacDonald, Sean Stevens, Samuel Davis, David R. Buckler, Karolina A. Hosiawa, Andrew J. Murphy
  • Publication number: 20120096572
    Abstract: Genetically modified mice and methods for making an using them are provided, wherein the mice comprise a replacement of all or substantially all immunoglobulin heavy chain V gene segments, D gene segments, and J gene segments with at least one light chain V gene segment and at least one light chain J gene segment. Mice that make binding proteins that comprise a light chain variable domain operably linked to a heavy chain constant region are provided. Binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Modified cells, embryos, and mice that encode sequences for making the binding proteins are provided.
    Type: Application
    Filed: August 2, 2011
    Publication date: April 19, 2012
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Cagan Gurer, Karolina A. Hosiawa, Andrew J. Murphy